25 General introduction 1 54. Vallance K, Liu W, Mandrell BN, et al: Mechanisms of dexamethasone-induced disturbed sleep and fatigue in paediatric patients receiving treatment for ALL. Eur J Cancer 46:1848-55, 2010 55. Yang L, Panetta JC, Cai X, et al: Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol 26:1932-9, 2008 56. Koltin D, Sung L, Naqvi A, et al: Medication induced diabetes during induction in pediatric acute lymphoblastic leukemia: prevalence, risk factors and characteristics. Support Care Cancer 20:2009-15, 2012 57. Schmiegelow K, Muller K, Mogensen SS, et al: Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy. F1000Res 6:444, 2017 58. Warris LT, van den Akker EL, Bierings MB, et al: Acute Activation of Metabolic Syndrome Components in Pediatric Acute Lymphoblastic Leukemia Patients Treated with Dexamethasone. PLoS One 11:e0158225, 2016 59. Chow EJ, Pihoker C, Friedman DL, et al: Glucocorticoids and insulin resistance in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 60:621-6, 2013 60. Pluimakers VG, van Waas M, Neggers S, et al: Metabolic syndrome as cardiovascular risk factor in childhood cancer survivors. Crit Rev Oncol Hematol 133:129-141, 2019 61. Misch M, Puthanveetil P: The Head-to-Toe Hormone: Leptin as an Extensive Modulator of Physiologic Systems. Int J Mol Sci 23, 2022 62. de Kloet ER: From receptor balance to rational glucocorticoid therapy. Endocrinology 155:275469, 2014 63. Reul JM, de Kloet ER: Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation. Endocrinology 117:2505-11, 1985 64. Sapolsky RM, Romero LM, Munck AU: How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev 21:55-89, 2000 65. Meijer OC, de Kloet ER: A Refill for the Brain Mineralocorticoid Receptor: The Benefit of Cortisol Add-On to Dexamethasone Therapy. Endocrinology 158:448-454, 2017 66. Gass P, Reichardt HM, Strekalova T, et al: Mice with targeted mutations of glucocorticoid and mineralocorticoid receptors: models for depression and anxiety? Physiol Behav 73:811-25, 2001 67. Rozeboom AM, Akil H, Seasholtz AF: Mineralocorticoid receptor overexpression in forebrain decreases anxiety-like behavior and alters the stress response in mice. Proc Natl Acad Sci U S A 104:4688-93, 2007 68. Lai M, Horsburgh K, Bae SE, et al: Forebrain mineralocorticoid receptor overexpression enhances memory, reduces anxiety and attenuates neuronal loss in cerebral ischaemia. Eur J Neurosci 25:1832-42, 2007 69. Otte C, Moritz S, Yassouridis A, et al: Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition. Neuropsychopharmacology 32:232-8, 2007 70. Kellner M, Wiedemann K: Mineralocorticoid receptors in brain, in health and disease: possibilities for new pharmacotherapy. Eur J Pharmacol 583:372-8, 2008 71. Klok MD, Alt SR, Irurzun Lafitte AJ, et al: Decreased expression of mineralocorticoid receptor mRNA and its splice variants in postmortem brain regions of patients with major depressive disorder. J Psychiatr Res 45:871-8, 2011 72. ter Heegde F, De Rijk RH, Vinkers CH: The brain mineralocorticoid receptor and stress resilience. Psychoneuroendocrinology 52:92-110, 2015
RkJQdWJsaXNoZXIy MTk4NDMw